Registry following people with lung cancer that has an MET exon 14 change
Collects long-term information on advanced lung cancer with MET exon 14 skipping treated with medicines.
Plain-language title generated from the registry record
Registry title: Met Non Small Cell Cancer Registry (MOMENT)
Key facts
- Where
- Ottawa, Québec, Toronto, and Vancouver, CanadaSee the 4 sites
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- How old is the patient who may join a trial?
Source: NCT05376891, who can take part
Where in Canada
- Ottawa Hospital - General CampusOttawa, CanadaTaking people
- Centre Intégré de Cancérologie du CHU de QuébecQuébec, CanadaTaking people
- Princess Margaret Cancer CentreToronto, CanadaTaking people
- British Columbia Cancer Agency (6864)Vancouver, CanadaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- EMD Serono Research & Development Institute, Inc.
- Trial code
- NCT05376891
- Record updated
- 29 October 2026
- Original description
The purpose of this multi-national disease registry is to collect prospectively (with longitudinal follow-up) high-quality, standardized, and contemporaneous data to capture changes in the non-small cell lung cancer (NSCLC) treatment landscape and outcomes over time.Read full original descriptionShow less
Disease Registry on Patients With Advanced NSCLC Harboring METex14 Skipping Alterations (MOMENT)
The purpose of this multi-national disease registry is to collect prospectively (with longitudinal follow-up) high-quality, standardized, and contemporaneous data to capture changes in the non-small cell lung cancer (NSCLC) treatment landscape and outcomes over time.
The registry will capture data on participants; demographic, clinical characteristics (including biomarker data), treatment patterns, and effectiveness and safety outcomes for advanced NSCLC with mesenchymal-epithelial transition exon 14(METex14) participants treated with systemic therapy.
Inclusion: Participants who signed ICF; Participants with advanced stage (stages IIIB-IV) NSCLC (all histologies) and Confirmed METex14 skipping alterations (by valid assay); Participants who are starting or are already being treated with systemic therapy.
Exclusion: Participants who are enrolled in a clinical trial.